Stocks erased earlier gains and traded lower Tuesday, as investors continued to eye states’ reopening plans and mulled recent corporate earnings results. Market participants also eyed the start of the Federal Reserve’s program to purchase corporate debt exchange-traded funds, which kicks off Tuesday.

from Yahoo Finance https://ift.tt/3cpZMw2

from Yahoo Finance https://ift.tt/3br1Fr1

Today we're going to take a look at the well-established Applied Materials, Inc. (NASDAQ:AMAT). The company's stock…

from Yahoo Finance https://ift.tt/2YW9WRe

Goldman Sachs's Marcus, CIT, Citibank, Ally, and many more popular online savings banks have lowered their rates, responding to the Fed's historic rate cut in March.

from Yahoo Finance https://ift.tt/2YXDxdd

Shares in home-fitness cycling company Peloton Interactive (PTON) have surged 10% in trading on May 12, bringing the stock’s year-to-date gain to over 65%. That’s after the company informed investors that it surpassed 1 million aggregate Connected Fitness subscribers.And now Andrew Left of Citron Research argues that enough is enough and investors should put Peloton into perspective: “This is retail mania – you can love the product, but stock has peddled its way to stupidity” tweeted the well-known activist short seller on May 12.As Left points out Peloton’s market cap has surged $5B this year; and with 300K connected subscribers that translates to $17K per subscriber.In contrast, the 2020 market cap for Teladoc (TDOC\- the telemedicine and virtual healthcare company) is up $8B vs. paid members up 6.2 million or $1300 per subscribers, Left tweeted.Nonetheless, five-star Stifel Nicolaus analyst Scott Devitt at Stifel Nicolaus has just raised his price target to $50 from $42, indicating 6% upside potential lies ahead. He also reiterated his Peloton buy rating.“Elevated demand for the company’s products has continued thus far into F4Q, with demand outpacing supply in most geographies,” Devitt explained, describing Peloton as “an unstoppable juggernaut to be stopped only by way of self-inflicted wound from here”.Indeed Wall Street analysts have an uniformly bullish outlook on Peloton stock. The Strong Buy consensus is due to 18 Buys ratings, vs just 1 Hold and 1 Sell.However, due to the recent rally, the $46.65 average price target now indicates that shares could pull back 1% from current levels- suggesting that, in this case, Left could be right. (See Peloton stock analysis on TipRanks).Related News: Peloton Shares Increase on 1 Million Fitness Subscriber Milestone Tesla’s Elon Musk to Reopen California Plant Despite Coronavirus Restrictions Microsoft to Splash $1.5 Billion on Italy’s Cloud Business Transformation More recent articles from Smarter Analyst: * Moderna’s Covid-19 Vaccine Candidate Gets FDA Fast Track Status * Hyatt Hotels Lays Off 1,300 Workers as Virus Pandemic Freezes Travel Demand * 2 Cruise Line Stocks to Bet on After the Coronavirus Crisis (And 1 to Avoid) * Peloton Shares Increase on 1 Million Fitness Subscriber Milestone

from Yahoo Finance https://ift.tt/2WuzhjP

Yahoo Finance’s Ethan Wolff-Mann joins Seana Smith to explain why Goldman Sachs is warning the U.S. may be undercounting coronavirus cases by a massive margin, after the crushing jobs numbers last Friday pointed to 20.5 million fewer payrolls in April compared to March.

from Yahoo Finance https://ift.tt/2LlSXzS

Luckin, a major rival to Starbucks in China, revealed in April that much of its 2019 sales of about 2.2 billion yuan ($310.77 million) were fabricated by its COO and other employees, who had been suspended while the company carried out its investigation. Jenny Zhiya Qian and Jian Liu, who were CEO and COO respectively, will also exit the company’s board. Meanwhile, Luckin’s chairman, Charles Zhengyao Lu, and Qian handed over shares in the coffee chain to lenders after a company controlled by Lu’s family defaulted on a $518 million margin loan.

from Yahoo Finance https://ift.tt/2YUTsZw

from Yahoo Finance https://ift.tt/3bnuWDb

Moderna Inc. (MRNA) announced on Tuesday that its experimental coronavirus vaccine has been granted fast track status by the U.S. Food and Drug Administration (FDA).The fast track status designation is awarded to speed up the regulatory review of its novel coronavirus vaccine candidate (mRNA-1273).Last week, the FDA completed its review of Moderna’s Investigational New Drug (IND) application for mRNA-1273 allowing it to proceed to a Phase 2 study, which is expected to begin shortly. The clinical stage biotech company said it is finalizing the protocol for a Phase 3 study, expected to begin in early summer of 2020.“Fast Track designation underscores the urgent need for a vaccine against the novel coronavirus,” said Tal Zaks, Chief Medical Officer at Moderna. “As we await the full set of clinical data from the NIAID-led Phase 1 study, we are actively preparing for our Phase 2 and Phase 3 clinical studies to continue learning about the potential of mRNA-1273 to protect against SARS-CoV-2.”By utilizing messenger RNA (mRNA) science, Moderna hopes to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases.Moderna shares dropped 2.7% to $65.04 in morning U.S. trading after the stock more than tripled this year.Five-star analyst Yasmeen Rahimi at Roth Capital raised Moderna’s price target to $68 from $41, while maintaining a Buy rating on the shares, saying that with the near-term start of a Phase 2 study for its COVID-19 vaccine, the company remains the front-runner in getting a vaccine to pivotal trials with potential approval by 2021.Although analysts have a Strong Buy consensus rating on Moderna stock based on 9 Buys and 2 Holds, its recent rally means that the $54.30 average price target now indicates 17% downside potential from current levels. (See Moderna stock analysis on TipRanks).Related News: Novavax Spikes 31% on $384 Million Cash Injection for Vaccine Production CymaBay Doubles After-Hours On Positive NASH Trial Update Genfit Craters 49% On Failed NASH Trial; Top Analyst ‘Not Surprised’ More recent articles from Smarter Analyst: * Hyatt Hotels Lays Off 1,300 Workers as Virus Pandemic Freezes Travel Demand * 2 Cruise Line Stocks to Bet on After the Coronavirus Crisis (And 1 to Avoid) * Peloton Shares Increase on 1 Million Fitness Subscriber Milestone * Logitech Leaps Almost 6% As Stay-At-Home Orders Boost Quarterly Sales

from Yahoo Finance https://ift.tt/2SYeWAV

Shares in CymaBay Therapeutics (CBAY) exploded over 105% in after-hours trading Monday after the company revealed a positive update for its seladelpar liver disease drug, which has been on clinical hold since November.Sujal Shah, President and CEO of CymaBay, stated, “Last week a panel of some of the most experienced and distinguished liver pathologists and hepatologists in the world completed an independent review analyzing findings from our Phase 2b study of seladelpar in patients with NASH.”“I am pleased to report that the panel unanimously concluded there was no clinical, biochemical or histological evidence of seladelpar-induced liver injury in the study, and as a result they also unanimously supported the lifting of the clinical hold and re-initiation of clinical development.”CymaBay now intends to reach out to the FDA to discuss all of the data it has collected to date and the results of the panel review meetings. Once initial feedback is gathered, CymaBay wants to submit a complete response to the seladelpar clinical hold to the FDA.At the same time the company announced Q1 GAAP EPS of -$0.19, which beat the Street consensus by $0.11. Research and development expenses for the three months ended March 31, 2020 were $9.5 million, compared to $18.6 million for the three months ended March 31, 2019.Meanwhile cash, equivalents and marketable securities came in at $176.23M (down 7.7% from the previous quarter). “We remain focused on cost containment and will look at additional steps we can take into fiscal year 2020 in order to closely control the Company’s operating expenses and associated cash burn” commented Shah.The Street gives CBAY a cautiously optimistic Moderate Buy analyst consensus with 3 recent buy ratings and 2 hold ratings. The average analyst price target stands at $2.78 (51% upside potential). (See CymaBay stock analysis on TipRanks).Related News: GW Pharma Pops 9% After-Hours As Epidiolex Smokes Expectations 3 Stocks Needham’s Top Analysts Are Raving About Solid Biosciences: Keep Your Eyes On The Prize Says Top Analyst More recent articles from Smarter Analyst: * Moderna’s COVID-19 Vaccine Candidate Gets FDA Fast Track Status * Hyatt Hotels Lays Off 1,300 Workers as Virus Pandemic Freezes Travel Demand * 2 Cruise Line Stocks to Bet on After the Coronavirus Crisis (And 1 to Avoid) * Peloton Shares Increase on 1 Million Fitness Subscriber Milestone

from Yahoo Finance https://ift.tt/2SZiwLa